Alkem Laboratories Limited (BOM:539523)
India · Delayed Price · Currency is INR | Market Cap | 606.19B -8.6% |
| Revenue (ttm) | 150.81B +13.4% |
| Net Income | 21.58B -5.6% |
| EPS | 180.45 -5.6% |
| Shares Out | n/a |
| PE Ratio | 28.12 |
| Forward PE | 25.17 |
| Dividend | 53.00 (1.05%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 1,994 |
| Open | 5,060.70 |
| Previous Close | 5,156.00 |
| Day's Range | 5,011.50 - 5,075.55 |
| 52-Week Range | 4,879.85 - 5,933.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 6,002.55 (+18.3%) |
| Est. Earnings | Nov 6, 2026 |
About Alkem Laboratories
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti – infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumato... [Read more]
Financial Performance
In fiscal year 2026, Alkem Laboratories's revenue was 147.12 billion, an increase of 13.48% compared to the previous year's 129.65 billion. Earnings were 23.02 billion, an increase of 6.30%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for 539523 stock is "Buy." The 12-month stock price target is ₹6,003, which is an increase of 18.30% from the latest price.
News
Alkem Laboratories Transcript: Q1 26/27
Q1 revenue rose ~11% YoY, with India and international sales growth and market outperformance. Net profit fell 21.7% on tax effects; Daman’s OAI and delayed CDMO break-even remain key risks, while FY27 guidance was maintained.
Alkem Laboratories Quarterly report: Q1 2027
Alkem Laboratories has published its Q1 2027 quarterly earnings report on August 14, 2026.
Alkem Laboratories Slides: Q1 2027
Alkem Laboratories has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 14, 2026.
Alkem Medtech executes supplementary agreement for Occlutech acquisition
Alkem Laboratories' subsidiary, Alkem Medtech, has taken a significant step in its acquisition of Occlutech Holding AG by executing a First Supplementary Agreement to the Share Purchase Agreement. Thi...
Alkem Laboratories launches semaglutide pre-filled syringes in India starting at Rs 350
Alkem Laboratories Ltd. has become the first company in India to launch semaglutide in single-shot pre-filled syringes, with prices starting at ₹350. This new delivery format aims to lower entry…
Alkem Laboratories shares rally over 6% after Q4 results; Revenue and EBITDA growth support sentiment
Shares of Alkem Laboratories rallied more than 6% in early trade on May 29 after the pharmaceutical company reported higher revenue and operating profit for the fourth quarter of FY26.…
Ashok Leyland, Wipro, Alkem Labs, Finolex Cables, Delta Corp, BDL, Zydus Life, HBL Engineering, Apar Industries, Indostar shares in focus today, May 29
Supreme Court ruling: Online gaming sector hit The Supreme Court upheld the 28% GST levy on online gaming platforms on the full face value of bets placed, with tax notices…
Stocks to watch today on brokerages: Bharat Dynamics, ONGC, Siemens, Ashok Leyland in focus on May 29
Several brokerage firms have issued fresh ratings, target price revisions, and outlook updates on key stocks including BDL, ONGC, Cummins India, Apar Industries, Alkem Laboratories, Ashok Leyland, Sie...
Alkem Laboratories Transcript: Q4 25/26
Record EBITDA and double-digit revenue growth achieved, driven by strong India and international performance, especially in chronic therapies and new launches like semaglutide. Margin guidance for FY27 is 20-21%, with ongoing cost pressures and a focus on execution and portfolio expansion.
Alkem Laboratories Quarterly report: Q4 2026
Alkem Laboratories has published its Q4 2026 quarterly earnings report on May 28, 2026.
Alkem Laboratories Slides: Q4 2026
Alkem Laboratories has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 28, 2026.
Alkem Laboratories Annual report: Q4 2026
Alkem Laboratories has published its Q4 2026 annual report on May 28, 2026.
Alkem Laboratories announces Rs 10 per share final dividend for FY26
Alkem Laboratories has announced a final dividend of ₹10 per equity share for the financial year ending 31st March 2026. This decision was made during the company's Board Meeting held…
Alkem Laboratories appoints Chanakya Misra to senior management position
Alkem Laboratories has announced the appointment of Mr. Chanakya Misra to a senior management position, effective from 18th May 2026. This strategic move is part of the company's ongoing efforts…
Alkem Laboratories sees US FDA inspection at Taloja facility with no form 483 issued
Alkem Laboratories' Contract Research Organisation (CRO) facility in Taloja, Maharashtra, underwent an unannounced inspection by the US Food and Drug Administration (FDA) on 8th May 2026. The inspecti...
Alkem Laboratories receives Form 483 with seven observations from US FDA
Alkem Laboratories has been issued a Form 483 with seven observations following an inspection by the US Food and Drug Administration (FDA) at its manufacturing facility in Amaliya, Daman. The…
Why are Alkem Laboratories shares falling sharply over 3% today? Explained
Shares of Alkem Laboratories declined more than 3% on April 24, 2026, after the company announced the resignation of its Chief Executive Officer and Key Managerial Personnel, Dr. Vikas Gupta.…
Alkem Laboratories CEO Vikas Gupta resigns; to step down by June 30
Alkem Laboratories Limited has announced the resignation of its Chief Executive Officer and Key Managerial Personnel, Dr. Vikas Gupta, who will step down from his role to pursue new professional…
Alkem Laboratories CEO Dr. Vikas Gupta resigns effective June 2026
Alkem Laboratories has announced the resignation of its Chief Executive Officer, Dr. Vikas Gupta. The resignation is effective from 30th June 2026, allowing for a smooth transition of responsibilities...
Alkem Laboratories sets up Dubai free zone subsidiary to drive pharma exports to Africa and South East Asia
Alkem Laboratories Limited has incorporated a wholly owned subsidiary in Dubai, UAE, named Alkem Pharma Trading FZCO, with the specific purpose of expanding pharmaceutical exports to African, South Ea...
Alkem Laboratories establishes wholly owned subsidiary in Dubai
Alkem Laboratories has announced the incorporation of a wholly owned subsidiary, Alkem Pharma Trading FZCO, in Dubai, UAE. The new entity has been established to facilitate the export of Alkem…
Alkem launches A to Z Daily multivitamin with 26 essential nutrients
Alkem Laboratories Ltd. has introduced a new multivitamin supplement, A to Z Daily, aimed at providing comprehensive nutritional support for both body and mind. The supplement is formulated with 26…
Alkem Laboratories increases investment to Rs 1,036 crore for Ujjain facility
Alkem Laboratories has announced an increase in its investment for a greenfield formulations manufacturing facility in Ujjain, Madhya Pradesh. The company has raised its investment from ₹533 crore to ...
Alkem Laboratories establishes wholly owned subsidiary in UAE
Alkem Laboratories has announced the incorporation of a new wholly owned subsidiary, Alkem Pharmaceuticals Scientific Office FZ LLC, in Dubai Healthcare City, UAE. The subsidiary will function as a 'S...
Alkem Laboratories launches semaglutide injection in India at Rs 450 weekly therapy cost
Alkem Laboratories has introduced semaglutide injection in India, targeting type-2 diabetes mellitus and chronic weight management. The therapy is priced at an accessible ₹450 per week, aiming to enha...